Table 1.
Characteristics of lung cancer patients undergoing treatment during the COVID‐19 pandemic period
| All patients | Patients with treatment delay | Patients without treatment delay | P‐value | |
|---|---|---|---|---|
| (n = 165) | (n = 15) | (n = 150) | ||
| Age | 70.2 ± 9.2 | 72.5 ± 9.2 | 70.0 ± 9.2 | 0.28 |
| Sex (female) | 62 (37.6) | 3 (20.0) | 59 (39.3) | 0.17 |
| Outpatient treatment | 136 (82.4) | 11 (73.3) | 125 (83.3) | 0.30 |
| Histopathology | ||||
| Adenocarcinoma | 99 (60.0) | 6 (40.0) | 93 (62.0) | 0.11 |
| Squamous cell carcinoma | 32 (19.4) | 5 (33.3) | 27 (18.0) | 0.17 |
| Small cell lung cancer | 18 (10.9) | 1 (6.7) | 17 (11.3) | >0.99 |
| Not otherwise specified | 15 (9.1) | 3 (20.0) | 12 (8.0) | 0.14 |
| Pleomorphic carcinoma | 1 (0.61) | 0 (0.0) | 1 (0.67) | >0.99 |
| Type of treatment | ||||
| Cytotoxic chemotherapy ± ICIs | 33 (20.0) | 3 (20.0) | 30 (20.0) | >0.99 |
| ICI monotherapy | 76 (46.1) | 12 (80.0) | 64 (42.7) | 0.0057 |
| Molecular targeted agents | 56 (33.9) | 0 (0.0) | 56 (37.3) | 0.0027 |
| Reason for treatment delay | ||||
| Doctor request | 2 (1.2) | 2 (13.3) | — | NE |
| Patient request | 12 (7.3) | 12 (80.0) | — | NE |
| Family request | 1 (0.61) | 1 (6.7) | — | NE |
Data are shown as number (%) or mean ± SD.
ICIs, immune checkpoint inhibitors; NE, not evaluated.